Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK06 in advanced or metastatic solid tumors
NCT06667960Phase 2Recruiting
- Sponsor
- Salubris Biotherapeutics
- Start
- Oct 2024
- Primary completion
- Apr 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 2, open-label trial of JK06 in solid tumor, sponsored by Salubris Biotherapeutics. Primary endpoints: Dose-limiting Toxicity at 21 days, Dose-Finding at 14 months and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
JK06
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06667960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667960.